Tenaya Therapeutics, Inc. Accounts Receivable, Allowance for Credit Loss
Tenaya Therapeutics, Inc. (TNYA) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-08-05
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2025-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2025-03-31: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |